Aspirin Mechanism of Action and Pathophysiology
Aspirin works by irreversibly acetylating serine-529 of the cyclooxygenase-1 (COX-1) enzyme in platelets, permanently blocking thromboxane A2 synthesis and thereby inhibiting platelet aggregation for the entire lifespan of the platelet. 1
Molecular Mechanism
Aspirin selectively acetylates the hydroxyl group of a single serine residue at position 529 (Ser529) within the polypeptide chain of platelet prostaglandin H-synthase (PGH-synthase). This enzyme has two catalytic activities:
- Cyclo-oxygenase (COX) activity: Converts arachidonic acid to PGG2
- Hydroperoxidase activity: Reduces PGG2 to PGH2
Through O-acetylation of Ser529, aspirin permanently destroys the cyclo-oxygenase activity while leaving the hydroperoxidase activity intact 1. This is a "hit-and-run" mechanism—aspirin permanently inactivates a platelet enzyme that cannot be resynthesized during a 24-hour dosing interval through a short-lived active moiety 1.
The Arachidonic Acid Pathway
When platelets are activated, phospholipases release arachidonic acid from membrane phospholipids. Normally, COX-1 converts this to PGH2, which is then converted to thromboxane A2 (TXA2) by thromboxane synthase. TXA2 is a potent vasoconstrictor and platelet aggregator that amplifies the platelet activation signal 1.
By blocking COX-1, aspirin prevents TXA2 formation, thereby suppressing this amplification loop of platelet activation and aggregation 1.
COX-1 vs COX-2 Selectivity
Aspirin inhibits both COX isoforms, but with different potencies:
- COX-1 (constitutive enzyme): Inhibited at low doses (75-100 mg daily)
- COX-2 (inducible enzyme): Requires higher concentrations for inhibition
This differential sensitivity explains why low doses provide antiplatelet effects while higher doses are needed for anti-inflammatory and analgesic effects 1. The antiplatelet effect is saturable at doses of 75-100 mg daily, as demonstrated by extensive randomized trial data 1.
Unique Pharmacological Properties
Despite aspirin's half-life of only 15-20 minutes in circulation 2, its antiplatelet effect lasts 24-48 hours because:
- The acetylation of COX-1 is irreversible
- Platelets cannot synthesize new COX-1 (they lack nuclei)
- The effect persists for the platelet's entire 7-10 day lifespan
- Only newly released platelets from bone marrow restore normal function
This explains why aspirin can be dosed once daily and why its effects persist for days after discontinuation 1.
Clinical Implications
The permanent platelet inhibition results in:
- Prolonged bleeding time detectable clinically 1
- Antithrombotic effects that prevent myocardial infarction and ischemic stroke 1
- Increased bleeding risk that cannot be dissociated from the therapeutic benefit 1
Important Caveats
Aspirin does not completely abolish platelet function. Under certain conditions—particularly with strong activators like high concentrations of thrombin or collagen—platelet aggregation can occur despite aspirin therapy because these pathways bypass the TXA2 amplification system 2. This explains why some patients experience thrombotic events despite aspirin therapy, though this should not be confused with true "aspirin resistance."
The biochemical selectivity of low-dose aspirin for platelet COX-1 over endothelial COX-2 arises from pharmacokinetic factors: platelet COX-1 is acetylated in portal blood before first-pass hepatic metabolism, while endothelial cells can regenerate COX-2 1.